India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Flood insurance premiums across Florida are climbing fast, with more than 80% of NFIP policyholders seeing annual increases under FEMA’s Risk Rating 2.0. Some counties now face hikes exceeding $3,500 per year, adding pressure in a state where homeowners insurance already averages nearly $11,000 annually. As risk-based pricing takes hold and climate impacts intensify, Florida homeowners — and the real estate pros who advise them — must prepare for continued premium growth and major county‑to‑county disparities.
As insurers step into 2026, the property and casualty market shows its first signs of real stability after several turbulent years. Q4 results reveal disciplined underwriting, cooling rate hikes, and steady premium growth across major carriers. Commercial lines show selective momentum, personal lines begin to level out, and AI-driven efficiency becomes the industry’s new engine for profitability. With catastrophe losses moderating and tech adoption accelerating, professionals across insurance, real estate, and finance can expect a pivotal year—and an ideal moment to sharpen their skills through continuing education.
A new CBRE survey shows that most U.S. commercial real estate investors expect to increase their property purchases in 2026, signaling renewed confidence and market stabilization. Dallas remains the nation’s top target for the fifth straight year, followed by high‑growth metros like Atlanta, San Francisco, Miami, Charlotte, Raleigh‑Durham, Nashville, Tampa, Seattle, and New York City. These cities continue to draw strong investor interest due to population growth, business expansion, and robust development activity.
Florida Insurance Commissioner Michael Yaworsky says the state's turbulent property insurance market is finally calming, with Florida posting the lowest rate increases in the nation last year. Yet rising home replacement costs mean many homeowners won’t see relief in their premiums just yet. With Citizens Insurance shrinking, new legislative priorities emerging, and long‑term reforms taking hold, Florida’s real estate and insurance professionals are entering 2026 with cautious optimism and a clearer picture of what’s ahead.
A new CBRE survey shows investor optimism surging as 95% plan to buy more or the same amount of commercial real estate in 2026, with over half increasing their capital allocation. Stabilizing values, improving fundamentals, and expected relief in debt costs are driving renewed confidence, putting markets like Dallas, Atlanta, and Tampa in the spotlight as multifamily and industrial assets lead demand.
Artificial intelligence has moved from industry buzzword to essential mortgage‑lending tool, reshaping how loan officers work, communicate and compete. From smarter lead targeting to rapid content creation and CRM‑powered automation, AI is now the dividing line between lenders who scale efficiently and those stuck in manual workflows. This article breaks down why AI adoption is no longer optional, how top lenders are using it and what mortgage professionals must do now to stay competitive.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
